Clinical Trial Update: PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating epoetin alfa (PROCRIT) 60,000 units given every two weeks in anemic cancer patients not receiving chemotherapy or radiation; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Anemia, Neoplasms | Phase 2 | Status: COMPLETED